Posted by Michael Wonder on 15 Sep 2016
NICE published draft guidance on new use for Gazyva
15 September 2016 - The Department of Health has asked the NICE to produce guidance on using obinutuzumab in combination with bendamustine in the NHS in England.
Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance is not recommended within its marketing authorisation for treating follicular lymphoma that did not respond or progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.
The appraisal committee will meet again on 18 October 2016 to consider the evidence, this appraisal consultation document and comments from the consultees.
